Dipeptidyl peptidase-4 inhibitors and cardiovascular risks in patients with pre-existing heart failure

Conclusions
In this nationwide T2DM cohort, the risks of mortality and the combination of MI and ischaemic stroke were lower for patients receiving DPP-4 inhibitors than for those who did not receive such treatment. DPP-4 inhibitor use was not associated with a higher risk of hospitalisation for HF even in patients with pre-existing HF.

Source: Heart - February 26, 2017 Category: Cardiology Authors: Ou, S.-M., Chen, H.-T., Kuo, S.-C., Chen, T.-J., Shih, C.-J., Chen, Y.-T. Tags: Health policy, Drugs: cardiovascular system, Acute coronary syndromes, Epidemiology, Diabetes, Metabolic disorders Heart failure and cardiomyopathies Source Type: research